Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENLV NASDAQ:NRSN NASDAQ:SCYX NASDAQ:SLXN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENLVEnlivex Therapeutics$1.45-2.7%$1.13$0.81▼$1.76$35.24M0.8231,549 shs250,283 shsNRSNNeuroSense Therapeutics$1.08-40.0%$1.97$0.60▼$2.60$24.60M1.66236,302 shs1.58 million shsSCYXSCYNEXIS$0.68-1.3%$0.77$0.66▼$2.00$26.58M1.64198,981 shs125,029 shsSLXNSilexion Therapeutics$9.28-37.9%$12.90$7.82▼$627.75$8.66M0.05161,285 shs359,370 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENLVEnlivex Therapeutics-2.68%+29.23%+28.32%+39.42%+8.21%NRSNNeuroSense Therapeutics-40.00%-46.80%-43.16%+4.85%+42.14%SCYXSCYNEXIS-1.30%-6.71%-5.42%-33.58%-68.02%SLXNSilexion Therapeutics-37.88%-28.36%-23.19%-38.13%+927,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENLVEnlivex Therapeutics2.1981 of 5 stars3.73.00.00.01.10.80.6NRSNNeuroSense Therapeutics2.0573 of 5 stars3.54.00.00.00.61.70.0SCYXSCYNEXIS0.4471 of 5 stars0.04.00.00.00.00.80.6SLXNSilexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENLVEnlivex Therapeutics 3.33Buy$10.00589.66% UpsideNRSNNeuroSense Therapeutics 3.00Buy$14.001,196.30% UpsideSCYXSCYNEXIS 0.00N/AN/AN/ASLXNSilexion Therapeutics 3.00Buy$75.00708.19% UpsideCurrent Analyst Ratings BreakdownLatest SLXN, SCYX, ENLV, and NRSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.007/22/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.007/10/2025NRSNNeuroSense TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.005/12/2025NRSNNeuroSense TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025NRSNNeuroSense TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.00 per shareN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/A$0.19 per shareN/ASCYXSCYNEXIS$2.63M10.11N/AN/A$1.45 per share0.47SLXNSilexion TherapeuticsN/AN/AN/AN/A($37.31) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENLVEnlivex Therapeutics-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)NRSNNeuroSense Therapeutics-$10.21M-$0.54N/A∞N/AN/AN/A-445.40%N/ASCYXSCYNEXIS-$21.29M-$0.56N/A13.62N/A-1,030.04%-53.47%-32.86%8/6/2025 (Estimated)SLXNSilexion Therapeutics-$16.44MN/A0.00∞N/AN/AN/A-359.62%8/7/2025 (Estimated)Latest SLXN, SCYX, ENLV, and NRSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/29/2025Q1 2025ENLVEnlivex Therapeutics-$0.16N/AN/AN/AN/AN/A8/14/2025Q2 2025SCYXSCYNEXIS-$0.23N/AN/AN/AN/AN/A5/30/2025Q1 2025ENLVEnlivex Therapeutics-$0.16-$0.15+$0.01-$0.15N/AN/A5/15/2025Q1 2025SCYXSCYNEXIS-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million5/13/2025N/ASLXNSilexion TherapeuticsN/A-$3.90N/A-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENLVEnlivex TherapeuticsN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ASLXNSilexion TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENLVEnlivex TherapeuticsN/A7.207.20NRSNNeuroSense TherapeuticsN/A2.212.21SCYXSCYNEXISN/A5.835.83SLXNSilexion Therapeutics1.163.223.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENLVEnlivex Therapeutics1.02%NRSNNeuroSense Therapeutics1.04%SCYXSCYNEXIS54.37%SLXNSilexion Therapeutics10.95%Insider OwnershipCompanyInsider OwnershipENLVEnlivex Therapeutics12.28%NRSNNeuroSense Therapeutics27.40%SCYXSCYNEXIS4.86%SLXNSilexion Therapeutics6.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENLVEnlivex Therapeutics7023.65 million20.75 millionOptionableNRSNNeuroSense Therapeutics1013.67 million9.92 millionNot OptionableSCYXSCYNEXIS6039.02 million37.12 millionOptionableSLXNSilexion TherapeuticsN/A580,000545,000N/ASLXN, SCYX, ENLV, and NRSN HeadlinesRecent News About These CompaniesSilexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross ProceedsJuly 31 at 8:00 PM | globenewswire.comSilexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS MutationJuly 31 at 9:55 AM | globenewswire.comSilexion Therapeutics Holds Annual General MeetingJuly 17, 2025 | theglobeandmail.comSilexion Therapeutics Announces 1-for-15 Reverse Share SplitJuly 16, 2025 | globenewswire.comSilexion Therapeutics Corp. Reports Positive Preclinical Data for ...July 11, 2025 | nasdaq.comSilexion Therapeutics Announces Positive Results in Preclinical Study ...July 11, 2025 | morningstar.comMSilexion Therapeutics receives Nasdaq panel approval for continued listingJuly 9, 2025 | uk.investing.comSilexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell LinesJuly 9, 2025 | globenewswire.comSilexion Therapeutics announces preclinical results on SIL204May 30, 2025 | finance.yahoo.comSilexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal TumorsMay 30, 2025 | msn.comSilexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung CancersMay 29, 2025 | finance.yahoo.comSilexion's SIL204 Completes Key Preclinical Studies In KRAS-Mutant CancersMay 23, 2025 | nasdaq.comSilexion Therapeutics Receives Nasdaq Delisting NoticeMay 23, 2025 | tipranks.comPESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer TreatmentMay 22, 2025 | globenewswire.comSilexion Therapeutics Corporation Registered ShsMay 22, 2025 | markets.businessinsider.comSilexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung CancerMay 21, 2025 | finance.yahoo.comSilexion Therapeutics Completes Preclinical Study on SIL204 for Expanded KRAS-Driven Cancer TherapiesMay 21, 2025 | quiverquant.comQSilexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung CancerMay 21, 2025 | globenewswire.comSilexion Therapeutics Corp: Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | finanznachrichten.deSilexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLXN, SCYX, ENLV, and NRSN Company DescriptionsEnlivex Therapeutics NASDAQ:ENLV$1.45 -0.04 (-2.68%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 08/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.NeuroSense Therapeutics NASDAQ:NRSN$1.08 -0.72 (-40.00%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.13 +0.05 (+4.63%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.SCYNEXIS NASDAQ:SCYX$0.68 -0.01 (-1.30%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.71 +0.03 (+4.68%) As of 08/1/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Silexion Therapeutics NASDAQ:SLXN$9.28 -5.66 (-37.88%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$9.28 +0.01 (+0.05%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
